VICTORIA, April 4, 2019 /CNW/ - IMMUNOPRECISE
ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC
PINK: IPATF) announces it has formed a wholly-owned, Cambridge, Massachusetts-based subsidiary,
Talem Therapeutics (Talem). Talem is focused on the discovery and
development of next-generation, fully-human, monoclonal therapeutic
antibodies targeting neurology, immuno-oncology, gastroenterology,
inflammation, and rare/specialty diseases. Using proprietary
antibody discovery platforms and innovative technologies, Talem
will be producing a rich pipeline of high quality and distinct
antibodies.
The demand for safe, therapeutic, monoclonal antibody (mAb)
candidates with more complex target product profiles is driving a
need for more robust discoveries. Talem was founded to expedite the
high-powered discovery and development of custom therapeutics
produced as both internal assets as well as in response to
partnership requests with large pharma.
Talem Therapeutics' strategy is to develop on-demand and
in-house antibodies through pre-clinical stage prior to licensing
for clinical partners. The speed and adaptability of IPAs platforms
enables Talem to quickly respond to targets based on years of
experience and expertise in the antibody discovery sector.
Along with the designated pre-clinical programs, Talem is also
engaging in negotiations on joint research and development
(R&D) programs with numerous pharmaceutical companies.
About Talem Therapeutics
Talem Therapeutics (www.talemtherapeutics.com) is an
international biopharmaceutical company focused on the discovery
and development of new antibodies originating from IPA's innovative
and proprietary technologies and Structure-Based Drug Design
platform capabilities. Talem will focus on a broad pipeline of
partnered and in-house drug candidates in multiple therapeutic
areas including, but not limited to, neurology, immuno-oncology,
gastroenterology, inflammation, and rare/specialty diseases.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is a full-service, therapeutic antibody discovery
company focused on the next generation of antibody discovery, to
deliver the most therapeutically-relevant antibodies, in a shorter
period of time, with the highest probability of succeeding to
clinical trials.
ImmunoPrecise operates from state-of-the-art laboratory
facilities located at the Vancouver Island Technology Park
in Victoria, British
Columbia, in collaboration with its wholly-owned subsidiary
operations at U-Protein Express B.V., in the Life Science
Incubator, Utrecht, and ModiQuest Research, Oss, both
in the Netherlands. The
Company operates globally to offer antibody services from target
analysis to pre-clinical studies.
The services offered to clients include antibody discovery
against a broad spectrum of antigens, including challenging
targets. Amongst these services, the Company offers hybridoma
production, B cell services, and a variety of phage display
platforms. The Company also provides a broad range of supporting
services including immunologically-based assays, recombinant
protein manufacturing, humanization, optimization, stable cell line
development, and advanced solutions to challenges faced by clients
in antibody-related research and development. The antibodies
produced by ImmunoPrecise target a wide variety of therapeutic,
diagnostic and research applications.
Forward Looking Information
This news release contains statements that, to the extent
they are not recitations of historical fact, may constitute
"forward-looking statements" within the meaning of applicable
Canadian securities laws. The Company uses words such as "may",
"would", "could", "will", "likely", "expect", "believe", "intend"
and similar expressions to identify forward-looking statements. Any
such forward-looking statements are based on assumptions and
analyses made by ImmunoPrecise in light of its experience and its
perception of historical trends, current conditions and expected
future developments. However, whether actual results and
developments will conform to ImmunoPrecise's expectations and
predictions is subject to any number of risks, assumptions and
uncertainties. Many factors could cause ImmunoPrecise's actual
results to differ materially from those expressed or implied by the
forward-looking statements contained in this news release. Such
factors include, among other things, actual revenues and earnings
for IPA being lower than anticipated, and those risks and
uncertainties described in ImmunoPrecise's annual management
discussion and analysis for the fiscal year ended April 30,
2018 which can be accessed at www.sedar.com. The
"forward-looking statements" contained herein speak only as of the
date of this press release and, unless required by applicable law,
ImmunoPrecise undertakes no obligation to publicly update or revise
such information, whether as a result of new information, future
events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE ImmunoPrecise Antibodies Ltd.